Lonsurf, a combination of trifluridine and tipiracil in pill form, is designed to treat advanced colorectal cancer patients who have had previous chemotherapy and biologic treatments. The drug has now received FDA approval, according to the American Gastroenterological Association.
Lonsurf's efficacy was analyzed in a double-blind study, according to the report. Patients receiving the newly-approved drug lived an average of 7.1 months, while patients treated with a placebo lived an average of 5.3 months.